Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novogene CoSHSE:688315 -2.93%84 PB Ratio is 1.86 as of Jul. 24, 2026, which is 56% below its 10-year median of 4.19. GuruFocus rates SHSE:688315 with a GF Score™ of 84/100 and a GF Value™ of ¥15.99 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,229 Biotechnology companies, Novogene Co ranks better than 64.04% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-24), Novogene Co's share price is ¥11.94. Novogene Co's Book Value per Share for the quarter that ended in Mar. 2026 was ¥6.43. Hence, Novogene Co's PB Ratio of today is 1.86.
Good Sign:
Novogene Co Ltd stock PB Ratio (=1.98) is close to 1-year low of 1.86.
The historical rank and industry rank for Novogene Co's PB Ratio or its related term are showing as below:
SHSE:688315'
s PB Ratio Range Over the Past 10 Years
Min: 1.59 Med: 4.19 Max: 20.33
Current: 1.86
During the past 11 years, Novogene Co's highest PB Ratio was 20.33. The lowest was 1.59. And the median was 4.19.
SHSE:688315's PB Ratio is ranked better than 64.04% of 1229
companies
in the Biotechnology industry
Industry Median: 2.79
vs SHSE:688315: 1.86
During the past 12 months, Novogene Co's average Book Value Per Share Growth Rate was 5.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 14.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 29.50% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Novogene Co was 187.60% per year. The lowest was 9.00% per year. And the median was 14.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Novogene Co PB Ratio Related Terms
Novogene Co PB Ratio Historical Data
* Premium members only.
The historical data trend for Novogene Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688315 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Novogene Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novogene Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novogene Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Novogene Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Novogene Co's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Novogene Co (SHSE:688315) has a PB Ratio of 1.86 as of Jul. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Novogene Co and its competitors. This is 56% below median its historical median of 4.19. Over the past decade, Novogene Co's PB Ratio has ranged from 1.59 to 20.33. According to the industry distribution chart, Novogene Co ranks #442 out of 1229 companies in the Biotechnology industry, placing it in the top 36%.
Is Novogene Co's PB Ratio too high?
Novogene Co's current PB Ratio of 1.86 is 56% below median its 10-year median of 4.19. Over the past 10 years, this metric has ranged from a low of 1.59 to a high of 20.33. The Biotechnology industry median PB Ratio is 2.79. Novogene Co's value of 1.86 is 33.3% below this industry median. Based on the distribution chart, Novogene Co ranks #442 out of 1229 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Novogene Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novogene Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Novogene Co ranks #442 out of 1229 companies for PB Ratio. This puts Novogene Co in the upper half of its industry. The industry median PB Ratio is 2.79. Novogene Co's value of 1.86 is 33.3% below this benchmark. Historically, Novogene Co's own PB Ratio has ranged from 1.59 to 20.33 over the past decade. While the company's 10-year median is 4.19 vs. the industry median of 2.79, Novogene Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novogene Co's current PB Ratio of 1.86 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Novogene Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novogene Co's current PB Ratio is 1.86, which is 56% below median its own 10-year median of 4.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novogene Co stock overvalued right now?
Based on GuruFocus' analysis, Novogene Co (SHSE:688315) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥15.99, compared to a current price of ¥11.94 — trading 25.3% below its estimated fair value. The current PB Ratio is 1.86, which is 56% below median its 10-year median of 4.19 and 33.3% below the Biotechnology industry median of 2.79. Novogene Co's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Novogene Co (SHSE:688315), the current PB Ratio is 1.86 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novogene Co (SHSE:688315) Overvalued in 2026?
Based on GuruFocus' analysis, Novogene Co stock appears to be undervalued.
The current stock price of ¥11.94 is trading 25.3% below its estimated GF Value™ of ¥15.99.
GuruFocus considers Novogene Co to be Modestly Undervalued.
Key valuation signals for SHSE:688315:
PB Ratio: 1.86 (56% below median its 10-year median of 4.19)
GF Value™: ¥15.99 vs. price of ¥11.94 (25.3% below fair value)
Industry Position: 33.3% below the Biotechnology median (#442 of 1229)
No single metric tells the full story. See the SHSE:688315 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.
84GF Score
Get the complete analysis for SHSE:688315
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688315 has been successfully added to your 
